DiNAQOR
@dinaqor.com
DiNAQOR is a genetic medicine platform company pioneering early-stage drug development and manufacturing to advance promising gene therapies to the clinic. Our patent-protected, industry leading platform is designed to overcome the challenges and limitations of advanced gene therapy development by using proprietary engineered heart tissue technology (EHT), a novel Loco-Regional Perfusion system (LRP) and a fully integrated manufacturing solution. Our company is headquartered in the Greater Zurich Area, Switzerland, with additional presence in Laguna Hills, California and Hamburg, Germany.
DiNAQOR's Company Logos
DiNAQOR's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#EE8D08
Tahiti Gold
238, 141, 8
35, 93, 48
0, 41, 97, 7
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#000000
Black
0, 0, 0
0, 0, 0
0, 0, 0, 100
About DiNAQOR
DiNAQOR is a pioneering life sciences platform company that focuses on developing and delivering gene therapies and other therapeutics through its proprietary human-based tissue drug development technology. Headquartered in Switzerland, with additional presence in Germany and the US, the company was founded by a team of experienced pharmaceutical and biotechnology executives and academics with extensive expertise in gene therapy and R&D. DiNAQOR's mission is to revolutionize treatments for patients with heart disease by developing innovative gene therapy solutions.
Specifically, they specialize in genetic cardiomyopathies, a heart muscle disease that can lead to heart failure. To accomplish their goals, DiNAQOR has established strategic partnerships and collaborations with renowned institutions and companies, such as Lonza and University Medical Center Hamburg-Eppendorf. They are committed to transforming the lives of patients through their novel gene therapy platform and ongoing pipeline development.
For more information, you can download their detailed company overview on their website. DiNAQOR is a brand that is dedicated to making a significant impact in the field of gene therapy and ultimately improving patients' lives
Company type
Privately Held
Year founded
2019
Company size
11-50 employees
